All News

If approved, cyclobenzaprine hydrochloride (HCl) will be the first member of a new class of analgesic drugs for fibromyalgia.

The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points.

The investigators also find that age of initiation and frequent use were not associated with a greater age-related cognitive decline.

The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.

The radiation emerging from these isotopes can be used in 2 different ways in cancer trials: imaging (detection of tumors) and therapy (destruction of tumors).

Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.

Abstract data presented in September demonstrate that the drug elicited strong antitumor activity in the second line in both platinum-sensitive and -resistant patients.

The tool is designed to address the nocebo effect, which was a concern of prescribers and other health care professionals.

The authors note that routine screening in patients with primary ciliary dyskinesia to help identify undiagnosed asthma.

Snehal Bhatt discusess the need to individualize antiplatelet therapy decisions based on a comprehensive assessment of each patient's unique risk factors for thrombosis and bleeding.

Measuring end points such as molecular response, cytokines, and histomorphometry may show a greater range of benefits.

A collaborative health care approach enhances patient outcomes and supports informed decision-making in antibiotic management.

Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.

Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.

The study authors add that the validation improved the risk score in additional community-acquired pneumonia cohorts, and clinical studies would assess the broad clinical applicability.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

Results of the study showed an inverse relationship between BMI and LDL cholesterol changes for those who adopt a low-carbohydrate diet.

Nemolizumab exclusively targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

The indication is for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

Rural pharmacies and hospitals face unique challenges in maintaining adequate staffing and drug supply inventory to serve patients who often travel long distance.

The approval builds on previous indications for tapinarof, an aryl hydrocarbon receptor agonist, for the topical treatment of atopic dermatitis.

Alison Moskowitz, MD, discusses the clinical considerations, dosing strategies, and the critical role of pharmacists in managing toxicities and tailoring treatment plans for dual-targeted therapy with ruxolitinib and duvelisib.

Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.

AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.

Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.

Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.

Despite the overall decline in medication non-adherence, adult patients with asthma are continuing to report taking less or skipping doses and refilling prescriptions later to save money.

Pharmacists can make a significant impact by providing medication management, promoting nonpharmacologic approaches, supporting patients through life transitions.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).